Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fel d 1 Monoclonal Antibodies in Allergic Conjunctivitis Due to Cat Allergy
NCT07675811Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of freneslerbart and mevonlerbart in allergic conjunctivitis (AC) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Ocular itch score at Day 8. Started Jul 2026; status: recruiting.
02
Drugs
freneslerbartmevonlerbart
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT07675811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07675811.